logo
logo

Windgap Medical, Inc. Closes Over $39 Million Of Series B-1 Investment, More Than Twenty Percent Over Its Initial Goal

Jan 20, 2022•over 3 years ago

Amount Raised

$39 Million

Round Type

series b

Watertown

Description

Windgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced today that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital. This equity round of investment expanded beyond an initial target of approximately $32 million due to strong investor interest. This equity financing is also supported by existing investors, including Shepherd Kaplan Krochuk (SKK) and Molex Ventures (a Koch Industries company), along with new investors including Cobro Ventures, and others.

Company Information

Company

Windgap Medical

Location

Watertown, South Dakota, United States

About

Windgap Medical, Inc. is an emerging, privately-held pharmaceutical company in the Greater Boston area focused on developing patient solutions with its patented wet/dry drug delivery platforms. Its first product is for the administration of epinephrine for anaphylaxis with additional products under development in a variety of markets. Find more information on www.windgapmedical.com and follow the company on LinkedIn. For Media Inquiries: Windgap Medical, Inc. Chris Stepanian, +1 617-440-3311 Chief Executive Officer 327988@email4pr.com SOURCE Windgap Medical, Inc.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech